Search results for " Vaccine"

showing 10 items of 680 documents

Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort Study

2022

Pneumococcal community-acquired pneumonia (CAP) is a leading cause of mortality. Following the introduction of pneumococcal conjugate vaccines (PCVs) in children, a decrease in the burden of the disease was reported. In parallel, an increase in non-vaccine serotypes was also noted. The objective of this study was to assess the current serotype-specific epidemiology of pneumococci among Italian older adults hospitalized for CAP. A prospective study was conducted between 2017 and 2020 in four Italian regions. Subjects aged ≥65 years hospitalized with confirmed CAP were tested for pneumococci using both pneumococcal urinary antigen and serotype-specific urine antigen tests able to identify all…

pneumococcal conjugate vaccinecommunity-acquired pneumonia (CAP); older adults; pneumococcal conjugate vaccines; pneumococcal pneumonia; Streptococcus pneumoniaeMicrobiology (medical)Streptococcus pneumoniaepneumococcal pneumoniaVirologypneumococcal conjugate vaccinescommunity-acquired pneumonia (CAP)community-acquired pneumonia (CAP); <i>Streptococcus pneumoniae</i>; pneumococcal pneumonia; pneumococcal conjugate vaccines; older adultsSettore MED/42 - Igiene Generale E ApplicataMicrobiologyolder adultsMicroorganisms
researchProduct

A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy

2013

Vaccination of all healthy children against rotavirus (RV) has been recommended, since the availability of vaccines, both in Europe (PIDJ) and Italy (pediatricians). The aims of universal vaccination against RV include the protection of children against moderate/severe gastroenteritis forms by RV (GARV), prevent hospitalizations, reduce the severity and duration of the disease, and reduce morbidity and socioeconomic costs. Payers need to informed regarding the efficacy and the healthcare utilization related to RV vaccination in order to decide in favour of its extensive implementation. The aim of this paper is to assess the clinical and financial impact of the extensive vaccination aganist …

prevention of rotavirus infectionvaccination against rotavirusrotaviruItalyNational Health ProgramsCost-Benefit Analysisrotavirus; prevention of rotavirus infection; vaccination against rotavirusVaccinationRotavirus VaccinesHumansVaccines AttenuatedSettore MED/42 - Igiene Generale E Applicata
researchProduct

La prevención de la rabia y la sanidad municipal en Valencia (1894-1916)

1998

Se estudia la introducción de la vacunación antirrábica en Valencia tras su descubrimiento por Pasteur en 1885. La investigación se ha realizado a partir de documentación de archivo y de prensa médica de la época. Su aplicación se enmarca dentro de la «medicina de laboratorio», mayoritariamente seguida por los integrantes del Cuerpo Municipal de Sanidad del Ayuntamiento valenciano y que permitió una estrecha relación con los laboratorios españoles y extranjeros situados en ese momento a la cabeza de la investigación bacteriológica.

rabiaUNESCO::CIENCIAS DE LA VIDA::Inmunología ::Vacunasvalència:CIENCIAS DE LA VIDA::Microbiología ::Bacteriología [UNESCO]UNESCO::CIENCIAS DE LA VIDA::Microbiología ::Bacteriología:CIENCIAS DE LA VIDA::Inmunología ::Vacunas [UNESCO]rabieslaboratoris bacteriològicsrabies vaccinelaboratorios bacteriológicosbacteriological laboratoriesvacuna antiràbicaUNESCO::HISTORIA::Historia por especialidades::Historia de la medicinaràbia:HISTORIA::Historia por especialidades::Historia de la medicina [UNESCO]valencevalenciavacuna antirrábica
researchProduct

RSV disease in infants and young children: Can we see a brighter future?

2022

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children &lt;5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclon…

respiratory syncytial virusImmunologyRSV vaccinesRespiratory Syncytial Virus InfectionsCommunicable DiseasesRSV preventionRSV all infantsImmunology and AllergyHumansChildmonoclonal antibodieRespiratory Tract InfectionsPharmacologyRSV all infantInfant NewbornRSVInfantAntibodies MonoclonalRSV paediatric burdenHospitalizationLRTIRSV epidemiologyChild PreschoolRespiratory Syncytial Virus HumanBronchiolitismonoclonal antibodiesLRTI; RSV; RSV all infants; RSV epidemiology; RSV paediatric burden; RSV prevention; RSV vaccines; monoclonal antibodies; respiratory syncytial virusRSV prevention: RSV vaccines.Human vaccinesimmunotherapeutics
researchProduct

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in h…

2021

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalent influenza vaccine (IIV4-SD) in adults aged ≥60 y. This Phase III, randomized, modified double-blind, active-controlled study enrolled 1,528 participants aged ≥60 y, randomized 1:1 to a single injection of IIV4-HD or IIV4-SD. Hemagglutination inhibition (HAI) geometric mean titers (GMTs) were measured at baseline and D 28 and seroconversion assessed. Safety was described for 180 d after vaccinat…

safetyAdultIMPACTInfluenza vaccineImmunologyimmunogenicityAntibodies ViralQuadrivalent Influenza Vaccineolder adultImmunogenicity VaccineDouble-Blind MethodInfluenza HumanMedicine and Health SciencesImmunology and AllergyMedicineHumansVaccines Combinedolder adultsPharmacologybusiness.industryImmunogenicityADULTSHemagglutination Inhibition TestsEFFICACYVirologyinfluenza vaccinationHigh-dose influenza vaccineVaccines InactivatedInfluenza VaccinesPhase III trialbusinessHuman vaccinesimmunotherapeutics
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

The Role of Existential Concerns in the Individual’s Decisions regarding COVID-19 Vaccine Uptake: A Survey among Non-Vaccinated Italian Adults during…

2022

Recent studies have suggested that health constructs embraced by the Terror Management Theory (TMT) and the Basic Psychological Needs Theory (BPNT) may drive individuals’ COVID-19 health-related decisions. This study examines the relationships between existential concerns (ECs; within the TMT), basic psychological needs (BPNs; within the BPNT) and COVID-19 vaccine hesitancy (VH), as well as the mediating role of negative attitudes toward COVID-19 vaccines. A cross-sectional survey was carried out from April to May 2021 on a sample of two hundred and eighty-seven adults (Mage = 36.04 ± 12.07; 59.9% females). Participants provided information regarding existential concerns, basic psychologica…

vaccine hesitancy; existential concerns; basic psychological needs; attitudes; COVID-19; Pfizer-BioNTech vaccine; AstraZeneca vaccinePharmacologyattitudesInfectious Diseasesexistential concernsDrug DiscoveryImmunologybasic psychological needsCOVID-19vaccine hesitancyPharmacology (medical)AstraZeneca vaccinePfizer-BioNTech vaccineVaccines
researchProduct

The linguistic construction of confirmation niches in online comment sequences

2018

This study starts from the consideration that new media are platforms where communication and language are re-negotiated to adapt new frames (e.g. new politeness, multimodal exchanges) and, in particular, that fora are participatory frameworks, that represent a mined engagement in writing practices (Stommel and Koole, 2010). Discussions are organised as multiparty conversations on several topics, written by participants (i.e website users accessing a parenting forum) at different levels of expertise about health issues (mostly earned through their experience of parenthood; Kata, 2010). the challenge in this paper is : 1) to study asynchronous forum as a talk-in -interaction venue, where seq…

web exchange writing practices confirmation niche echo chamber vaccineSettore L-LIN/12 - Lingua E Traduzione - Lingua Inglese
researchProduct